Cannabis Law Report

JUNE 19, 2022

Unlike novel chemical compounds that are synthetically produced in the pharmaceutical industry through drug development programs, psychedelic compounds have a long and established history. As we see more data emerge from clinical trials, we are likely to see patent applications covering stability, pharmacokinetic, and pharmacodynamic data.

Clinical Trials 52

Clinical Trials Microdosing Data Pharmaceutical 52

Cannabis Law Report

FEBRUARY 9, 2022

But this is the first time Oregonians have been allowed to see some of the nuts and bolts of what some predict could grow into a billion-dollar industry nationally, according to Data Bridge Market Research. For example, there’s a desire among some people to microdose psilocybin, that is taking very small amounts every few days.

Clinical Trials 52

Clinical Trials Microdosing Safety Conditions 52

CannaMD

OCTOBER 7, 2019

In 2011, researchers published cross-sectional data from two population-based surveys including over 50,000 respondents. Researchers also point out: For many patients, cannabis may be a better option for weight loss than surgery or pharmaceuticals. Believe it or not, science says: YES. Take the American Journal of Epidemiology.

Marijuana 105

Marijuana Cannabinoids Patients Conditions 105

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Jonathan is the CEO and founder of Gilgamesh Pharmaceuticals. Rick Doblin, Ph.D, in/rickdoblin/ [link]. in/ronanlevy/.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51